MarketPulse

IND-enabling studies

2 articles
BenzingaBenzinga··Prnewswire

Kazia Therapeutics Bolsters Oncology Pipeline with First-in-Class SETDB1 Inhibitor

Kazia in-licenses SETDB1 epigenetic platform from QIMR Berghofer to develop immunotherapy-resistant cancer treatment.
KZIAdrug developmentoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Ac Immune Sa

AC Immune, Lilly Expand Tau Partnership With $11M Upfront as Alzheimer's Race Heats Up

AC Immune and Eli Lilly amend collaboration to advance tau-targeting Alzheimer's candidates, with $11M upfront and IND studies starting mid-2026.
LLYACIUneurodegenerative diseasesAlzheimer's disease